Cargando…

Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock

BACKGROUND: Although some studies conducted outside of Japan have addressed the effectiveness of intravenous immunoglobulins (IVIG) in treating infections, the dosing regimens and amounts used in Japan are very different from those reported. Here, we investigate the effectiveness of single-dose admi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamano, Nobuyuki, Nishi, Kenichiro, Onose, Aki, Okamoto, Akihisa, Umegaki, Takeshi, Yamazaki, Etsuko, Hirota, Kiichi, Ookura, Hiroe, Takahashi, Hakuo, Shingu, Koh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336264/
https://www.ncbi.nlm.nih.gov/pubmed/25705399
http://dx.doi.org/10.1186/2052-0492-1-4
_version_ 1782358438426181632
author Hamano, Nobuyuki
Nishi, Kenichiro
Onose, Aki
Okamoto, Akihisa
Umegaki, Takeshi
Yamazaki, Etsuko
Hirota, Kiichi
Ookura, Hiroe
Takahashi, Hakuo
Shingu, Koh
author_facet Hamano, Nobuyuki
Nishi, Kenichiro
Onose, Aki
Okamoto, Akihisa
Umegaki, Takeshi
Yamazaki, Etsuko
Hirota, Kiichi
Ookura, Hiroe
Takahashi, Hakuo
Shingu, Koh
author_sort Hamano, Nobuyuki
collection PubMed
description BACKGROUND: Although some studies conducted outside of Japan have addressed the effectiveness of intravenous immunoglobulins (IVIG) in treating infections, the dosing regimens and amounts used in Japan are very different from those reported. Here, we investigate the effectiveness of single-dose administration of IVIG in sepsis patients in Japan. METHODS: We analyzed 79 patients admitted to the intensive care unit (ICU) of a tertiary care institution due to severe sepsis or septic shock. Patients were randomly divided into a group that was administered standard divided doses of IVIG (5 g/day for 3 days, designated the S group) or a group that was administered a standard single dose of IVIG (15 g/day for 1 day, H group); freeze-dried sulfonated human IVIG was used. The longitudinal assessment of procalcitonin (PCT) levels, C-reactive protein (CRP) levels, white blood cell count, blood lactate levels, IL-6 levels, Sequential Organ Failure Assessment (SOFA) score, and Systemic Inflammatory Response Syndrome (SIRS) was conducted. We also assessed mechanical ventilation duration (days), ICU stay (days), 28-day survival rate, and 90-day survival rate. RESULTS: The study showed no significant differences in PCT levels, CRP levels, 28-day survival rate, and 90-day survival rate between the two groups. However, patients in the H group showed improvements in the various SIRS diagnostic criteria, IL-6 levels, and blood lactate levels in the early stages after IVIG administration. In light of the non-recommendation of IVIG therapy in the Surviving Sepsis Campaign Guidelines 2012, our findings of significant early post-administration improvements are noteworthy. IVIG's anti-inflammatory effects may account for the early reduction in IL-6 levels after treatment, and the accompanying improvements in microcirculation may improve blood lactate levels and reduce SOFA scores. However, the low dosages of IVIG in Japan may limit the anti-cytokine effects of this treatment. Further studies are needed to determine appropriate treatment regimens of single-dose IVIG. CONCLUSIONS: In this study, we investigated the effectiveness of single-dose IVIG treatment in patients with severe sepsis or septic shock. Although there were no significant effects on patient prognoses, patients who were administered single-dose IVIG showed significantly improved IL-6 levels, blood lactate levels, and disease severity scores.
format Online
Article
Text
id pubmed-4336264
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43362642015-02-22 Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock Hamano, Nobuyuki Nishi, Kenichiro Onose, Aki Okamoto, Akihisa Umegaki, Takeshi Yamazaki, Etsuko Hirota, Kiichi Ookura, Hiroe Takahashi, Hakuo Shingu, Koh J Intensive Care Research BACKGROUND: Although some studies conducted outside of Japan have addressed the effectiveness of intravenous immunoglobulins (IVIG) in treating infections, the dosing regimens and amounts used in Japan are very different from those reported. Here, we investigate the effectiveness of single-dose administration of IVIG in sepsis patients in Japan. METHODS: We analyzed 79 patients admitted to the intensive care unit (ICU) of a tertiary care institution due to severe sepsis or septic shock. Patients were randomly divided into a group that was administered standard divided doses of IVIG (5 g/day for 3 days, designated the S group) or a group that was administered a standard single dose of IVIG (15 g/day for 1 day, H group); freeze-dried sulfonated human IVIG was used. The longitudinal assessment of procalcitonin (PCT) levels, C-reactive protein (CRP) levels, white blood cell count, blood lactate levels, IL-6 levels, Sequential Organ Failure Assessment (SOFA) score, and Systemic Inflammatory Response Syndrome (SIRS) was conducted. We also assessed mechanical ventilation duration (days), ICU stay (days), 28-day survival rate, and 90-day survival rate. RESULTS: The study showed no significant differences in PCT levels, CRP levels, 28-day survival rate, and 90-day survival rate between the two groups. However, patients in the H group showed improvements in the various SIRS diagnostic criteria, IL-6 levels, and blood lactate levels in the early stages after IVIG administration. In light of the non-recommendation of IVIG therapy in the Surviving Sepsis Campaign Guidelines 2012, our findings of significant early post-administration improvements are noteworthy. IVIG's anti-inflammatory effects may account for the early reduction in IL-6 levels after treatment, and the accompanying improvements in microcirculation may improve blood lactate levels and reduce SOFA scores. However, the low dosages of IVIG in Japan may limit the anti-cytokine effects of this treatment. Further studies are needed to determine appropriate treatment regimens of single-dose IVIG. CONCLUSIONS: In this study, we investigated the effectiveness of single-dose IVIG treatment in patients with severe sepsis or septic shock. Although there were no significant effects on patient prognoses, patients who were administered single-dose IVIG showed significantly improved IL-6 levels, blood lactate levels, and disease severity scores. BioMed Central 2013-10-23 /pmc/articles/PMC4336264/ /pubmed/25705399 http://dx.doi.org/10.1186/2052-0492-1-4 Text en © Hamano et al.; licensee BioMed Central Ltd. 2013 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Hamano, Nobuyuki
Nishi, Kenichiro
Onose, Aki
Okamoto, Akihisa
Umegaki, Takeshi
Yamazaki, Etsuko
Hirota, Kiichi
Ookura, Hiroe
Takahashi, Hakuo
Shingu, Koh
Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
title Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
title_full Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
title_fullStr Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
title_full_unstemmed Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
title_short Efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
title_sort efficacy of single-dose intravenous immunoglobulin administration for severe sepsis and septic shock
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336264/
https://www.ncbi.nlm.nih.gov/pubmed/25705399
http://dx.doi.org/10.1186/2052-0492-1-4
work_keys_str_mv AT hamanonobuyuki efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT nishikenichiro efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT onoseaki efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT okamotoakihisa efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT umegakitakeshi efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT yamazakietsuko efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT hirotakiichi efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT ookurahiroe efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT takahashihakuo efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock
AT shingukoh efficacyofsingledoseintravenousimmunoglobulinadministrationforseveresepsisandsepticshock